155 related articles for article (PubMed ID: 33755451)
1. The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer.
Quiroz RV; Reutershan MH; Schneider SE; Sloman D; Lacey BM; Swalm BM; Yeung CS; Gibeau C; Spellman DS; Rankic DA; Chen D; Witter D; Linn D; Munsell E; Feng G; Xu H; Hughes JME; Lim J; Saurí J; Geddes K; Wan M; Mansueto MS; Follmer NE; Fier PS; Siliphaivanh P; Daublain P; Palte RL; Hayes RP; Lee S; Kawamura S; Silverman S; Sanyal S; Henderson TJ; Ye Y; Gao Y; Nicholson B; Machacek MR
J Med Chem; 2021 Apr; 64(7):3911-3939. PubMed ID: 33755451
[TBL] [Abstract][Full Text] [Related]
2. Targeting protein arginine methyltransferase 5 in cancers: Roles, inhibitors and mechanisms.
Chen Y; Shao X; Zhao X; Ji Y; Liu X; Li P; Zhang M; Wang Q
Biomed Pharmacother; 2021 Dec; 144():112252. PubMed ID: 34619493
[TBL] [Abstract][Full Text] [Related]
3. Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.
Zhu K; Song JL; Tao HR; Cheng ZQ; Jiang CS; Zhang H
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3693-3699. PubMed ID: 30366617
[TBL] [Abstract][Full Text] [Related]
4. Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
Zhu K; Shao J; Tao H; Yan X; Luo C; Zhang H; Duan W
J Comput Aided Mol Des; 2019 Aug; 33(8):775-785. PubMed ID: 31312965
[TBL] [Abstract][Full Text] [Related]
5. Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Wang Y; Hu W; Yuan Y
J Med Chem; 2018 Nov; 61(21):9429-9441. PubMed ID: 29870258
[TBL] [Abstract][Full Text] [Related]
6. Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations.
Ji S; Ma S; Wang WJ; Huang SZ; Wang TQ; Xiang R; Hu YG; Chen Q; Li LL; Yang SY
Chem Biol Drug Des; 2017 Apr; 89(4):585-598. PubMed ID: 27714957
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations.
Zhu K; Jiang C; Tao H; Liu J; Zhang H; Luo C
Bioorg Med Chem Lett; 2018 May; 28(9):1476-1483. PubMed ID: 29628326
[TBL] [Abstract][Full Text] [Related]
8. Targeting protein arginine methyltransferase 5 in disease.
Richters A
Future Med Chem; 2017 Nov; 9(17):2081-2098. PubMed ID: 29076773
[TBL] [Abstract][Full Text] [Related]
9. Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening.
Ye Y; Zhang B; Mao R; Zhang C; Wang Y; Xing J; Liu YC; Luo X; Ding H; Yang Y; Zhou B; Jiang H; Chen K; Luo C; Zheng M
Org Biomol Chem; 2017 May; 15(17):3648-3661. PubMed ID: 28397890
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel PRMT5 Inhibitors by Virtual Screening and Biological Evaluations.
Tao H; Yan X; Zhu K; Zhang H
Chem Pharm Bull (Tokyo); 2019; 67(4):382-388. PubMed ID: 30930442
[TBL] [Abstract][Full Text] [Related]
11. Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5.
Rong D; Zhou K; Fang W; Yang H; Zhang Y; Shi Q; Huang Y; Li J; Dong H; Li L; Ding J; Huang X; Wang Y
J Med Chem; 2022 Jun; 65(11):7854-7875. PubMed ID: 35612488
[TBL] [Abstract][Full Text] [Related]
12. Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
Mao R; Shao J; Zhu K; Zhang Y; Ding H; Zhang C; Shi Z; Jiang H; Sun D; Duan W; Luo C
J Med Chem; 2017 Jul; 60(14):6289-6304. PubMed ID: 28650658
[TBL] [Abstract][Full Text] [Related]
13. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of
Smith CR; Aranda R; Bobinski TP; Briere DM; Burns AC; Christensen JG; Clarine J; Engstrom LD; Gunn RJ; Ivetac A; Jean-Baptiste R; Ketcham JM; Kobayashi M; Kuehler J; Kulyk S; Lawson JD; Moya K; Olson P; Rahbaek L; Thomas NC; Wang X; Waters LM; Marx MA
J Med Chem; 2022 Feb; 65(3):1749-1766. PubMed ID: 35041419
[TBL] [Abstract][Full Text] [Related]
14. Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors.
Lin H; Luengo JI
Bioorg Med Chem Lett; 2019 Jun; 29(11):1264-1269. PubMed ID: 30956011
[TBL] [Abstract][Full Text] [Related]
15. Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders.
Shen Y; Gao G; Yu X; Kim H; Wang L; Xie L; Schwarz M; Chen X; Guccione E; Liu J; Bedford MT; Jin J
J Med Chem; 2020 Sep; 63(17):9977-9989. PubMed ID: 32787082
[TBL] [Abstract][Full Text] [Related]
16. Protein arginine methyltransferase 5: a potential cancer therapeutic target.
Yuan Y; Nie H
Cell Oncol (Dordr); 2021 Feb; 44(1):33-44. PubMed ID: 33469838
[TBL] [Abstract][Full Text] [Related]
17. Medicinal chemistry strategies targeting PRMT5 for cancer therapy.
Fu S; Zheng Q; Zhang D; Lin C; Ouyang L; Zhang J; Chen L
Eur J Med Chem; 2022 Dec; 244():114842. PubMed ID: 36274274
[TBL] [Abstract][Full Text] [Related]
18. EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma.
Liu X; He J; Mao L; Zhang Y; Cui W; Duan S; Jiang A; Gao Y; Sang Y; Huang G
Exp Eye Res; 2021 Jan; 202():108286. PubMed ID: 33035554
[TBL] [Abstract][Full Text] [Related]
19. Identification of 5-benzylidene-2-phenylthiazolones as potent PRMT5 inhibitors by virtual screening, structural optimization and biological evaluations.
Zhu K; Tao H; Song JL; Jin L; Zhang Y; Liu J; Chen Z; Jiang CS; Luo C; Zhang H
Bioorg Chem; 2018 Dec; 81():289-298. PubMed ID: 30172110
[TBL] [Abstract][Full Text] [Related]
20. Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
Sloan SL; Renaldo KA; Long M; Chung JH; Courtney LE; Shilo K; Youssef Y; Schlotter S; Brown F; Klamer BG; Zhang X; Yilmaz AS; Ozer HG; Valli VE; Vaddi K; Scherle P; Alinari L; Kisseberth WC; Baiocchi RA
PLoS One; 2021; 16(5):e0250839. PubMed ID: 33989303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
